Novo Nordisk's China Filing Offers a Counterweight to US Pricing Pressure

Novo Nordisk's oral Wegovy China application accepted; stock down 27% from high as investors await Sept 21 strategy update.

The Danish pharma giant has quietly added a new piece to its global growth puzzle. Chinese regulators accepted Novo Nordisk's application for its oral Wegovy tablet in late August, a development that gives investors something to hold onto as they await the company's pivotal capital markets day later this month.

The acceptance arrived just days after the pill version of Wegovy made its German market debut, underscoring how the company is leaning on international expansion to offset headwinds closer to home. China represents one of the largest untapped patient populations for obesity and diabetes therapies, though the company has not indicated a timeline for a potential approval.

The September 21 Reckoning

All eyes now turn to September 21, when management will lay out its strategic roadmap for the coming years. That event has taken on outsized importance given the skepticism that has crept into analyst commentary and the stock's lackluster performance.

The shares have been trading in the shadow of their January peak. At Friday's close of 40.09 euros, the stock sits roughly 27 percent below its 52-week high of 54.86 euros, with a year-to-date decline of 8.9 percent. Over a twelve-month horizon, the drop extends to 17 percent. Technical indicators suggest a market in equilibrium rather than distress: the shares hover near their 200-day moving average of 40.16 euros, while the relative strength index of 48.2 points to neither overbought nor oversold conditions.

The Price Concession Calculus

The central tension for Novo Nordisk lies in the trade-off between market access and margin preservation in the United States. Under commitments made in November, the company agreed to offer semaglutide-based products including Wegovy and Ozempic at 350 dollars per month through the TrumpRx program, which encompasses Medicare, Medicaid, and a direct distribution channel. Its insulin products NovoLog and Tresiba are slated for 35 dollars monthly through the same route.

These concessions secure continued access to the company's most important market but carve into the profitability of what has been its primary growth engine. The strategic logic appears to be that volume retention in the US, combined with new markets like China, can compensate for thinner per-unit economics.

Analyst Divergence Reflects the Uncertainty

The Street remains split on how this all nets out. Deutsche Bank downgraded the stock to Sell from Hold in late August, trimming its price target to 265 Danish kroner from 290, citing growth concerns and uncertainty ahead of the capital markets day. Citi reaffirmed its own Sell rating with a matching 265 kroner target in early September, pointing to decelerating GLP-1 prescription trends.

JPMorgan strikes a more measured tone. After management meetings, the bank held its Neutral stance with a 275 kroner price target, flagging the oral Wegovy launch as a potential catalyst. The divergence among these views captures the fundamental question: can geographic expansion and a new pill formulation offset US pricing pressure and intensifying competition?

Eli Lilly Looms Larger

The competitive backdrop has grown more demanding. Eli Lilly recently secured FDA approval for Mounjaro to reduce cardiovascular risk in type-2 diabetes patients with elevated heart risk, broadening its assault on the GLP-1 market where Novo Nordisk has historically held sway with Wegovy and Rybelsus. Analysts view this as a structural challenge that could weigh on the Danish company's growth trajectory for years.

The China filing, while early-stage, offers a potential counterweight. Successfully cracking the Chinese obesity market could help offset some of the US pricing givebacks, even as the race with Eli Lilly for international share intensifies. Until the September 21 investor day provides clarity on growth forecasts for China and other emerging markets — and how management intends to protect profitability amid US price cuts — the stock may remain caught between these competing forces. The regulatory acceptance in Beijing at least hands Novo Nordisk a tangible positive to build on, even if full market approval remains a distant milestone.